Biotie Buys VC-Backed Synosia Therapeutics

Biotie, a Finland-based drug development company, has agreed to pay 93.6 million euros ($127 million) for Switzerland-based biotherapeutics company Synosia Therapeutics, providing an exit for a slew of venture investors. 5AM Ventures, Aravis SA, Investor Growth Capital, Novo A/S, Swiss Helvetia Fund, UCB S.A., Versant Venture Management and Abingworth Management had backed Synosia.

North AmericaUSBriefs